LCLAT1 (lysocardiolipin acyltransferase 1) is a critical enzyme that catalyzes the reacylation of lysocardiolipin to cardiolipin, playing essential roles in mitochondrial membrane integrity and cellular lipid metabolism 1. The enzyme exhibits multiple acyltransferase activities, including cardiolipin remodeling and phosphatidylinositol acyl-chain modification, with preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. LCLAT1 operates through regulation of mitochondrial dynamics and mitophagy via the AMPK pathway, maintaining mitochondrial homeostasis 1. The gene demonstrates significant disease relevance across multiple conditions. In diabetic kidney disease, LCLAT1 upregulation promotes abnormal cardiolipin remodeling, leading to increased oxidized cardiolipin production and mitochondrial dysfunction in podocytes 1. Additionally, LCLAT1 is required for EGF-mediated phosphatidylinositol-3,4,5-trisphosphate generation and Akt signaling, indicating its involvement in growth factor signaling pathways 2. Clinically, LCLAT1 serves as a potential biomarker in various cancers, with overexpression associated with poor prognosis in hepatocellular carcinoma and involvement in immune evasion mechanisms 3. The enzyme also shows associations with erectile dysfunction susceptibility through effects on mitochondrial function and lipid metabolism 4. These findings establish LCLAT1 as a multifunctional enzyme critical for mitochondrial health and cellular signaling.